Browsing: SUSTAIN 11

Semaglutide vs Mealtime Insulin Aspart for Basal Insulin Intensification: SUSTAIN 11 Trial

By Hormone Insight Editorial TeamNovember 29, 20240

Summary: In 1,748 adults with T2D (HbA1c 7.5-10.0%) inadequately controlled on basal insulin glargine and metformin, once-weekly semaglutide 1.0 mg…

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

CONTACT INFO

Privacy Policy
Disclaimer

Browsing: SUSTAIN 11

Semaglutide vs Mealtime Insulin Aspart for Basal Insulin Intensification: SUSTAIN 11 Trial

Once-Weekly Semaglutide Shows Promise in Improving Glycaemic Control and Weight Loss for Type 2 Diabetes Patients, Study Finds

Study Finds Semaglutide Reduces Cardiovascular Risk in Type 2 Diabetes Patients, but Raises Retinopathy Concerns

Study Shows Once-Weekly Semaglutide Effectively Lowers Blood Sugar and Aids Weight Loss in Type 2 Diabetes Patients

Once-Weekly Semaglutide Outperforms Daily Sitagliptin in Blood Sugar and Weight Control for Type 2 Diabetes Patients

Subscribe now

CATEGORIES

CONTACT INFO